XML 91 R16.htm IDEA: XBRL DOCUMENT

Note 1 - Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

		September 30, 2020
										Gross				Gross
		*Amortized*				*Accrued*				*Unrealized*				*Unrealized*				*Estimated*
		*Cost*				*Interest*				*Gains*				*Losses*				*Fair Value*
Obligations of U.S. Government and its agencies		$	45,722			$	18			$	6			$	-			$	45,746
Corporate debt securities			590				4				-				-				594
Certificates of deposit			3,477				9				3				-				3,489
Total investments		$	49,789			$	31			$	9			$	-			$	49,829

			December 31, 2019
										Gross				Gross
		*Amortized*				*Accrued*				*Unrealized*				*Unrealized*				*Estimated*
		*Cost*				*Interest*				*Gains*				*Losses*				*Fair Value*
Obligations of U.S. Government and its agencies		$	10,488				50			$	23			$	-			$	10,561
Corporate debt securities			9,742				59				10				(1	)			9,810
Certificates of deposit			1,669				7				7				-				1,683
Total investments		$	21,899				116			$	40			$	(1	)		$	22,054

Available For Sale Securities Debt Maturities Fair Value [Table Text Block]

		September 30, 2020				December 31, 2019
Maturing in one year or less		$	46,827			$	22,054
Maturing after one year through two years			3,002				-
Total investments		$	49,829			$	22,054

Schedule of Receivables from Collaborations [Table Text Block]

			September 30, 2020
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	-			$	3,547			$	3,547
Shionogi & Co. Ltd.			1,679				4				1,683
Green Cross Corporation			142				8				150
Mundipharma International Holdings Limited			42				-				42
Total receivables		$	1,863			$	3,559			$	5,422

			December 31, 2019
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	1,353			$	15,023			$	16,376
Shionogi & Co. Ltd.			1,336				4				1,340
Green Cross Corporation			2,924				8				2,932
Mundipharma International Holdings Limited			56				-				56
Seqirus UK Limited			1,091				351				1,442
Total receivables		$	6,760			$	15,386			$	22,146

Disaggregation of Revenue [Table Text Block]

		Three Months								Nine Months
		2020				2019				2020				2019
Product sales		$	2,478			$	335			$	2,696			$	2,014
Royalty revenue			254				508				2,243				3,526
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services			3,088				932				7,240				3,570
Torii Pharmaceutical Co., Ltd.			282				—				1,617				—
Total collaborative and other research and development revenues			3,370				932				8,857				3,570
Total revenues		$	6,102			$	1,775			$	13,796			$	9,110